Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aprepitant

Next Previous
X
Search
Drug Profile

Aprepitant

Alternative Names: Emend; L-754030; MK-0869; MK-869; ONO-7436

Latest Information Update: 25 Sep 2021

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Fudan University Shanghai Cancer Center; Hunan Province Tumor Hospital; Merck & Co; Ono Pharmaceutical
  • Class Anti-inflammatories; Antidepressants; Antiemetics; Antineoplastics; Antitussives; Antivirals; Fluorobenzenes; Ketones; Morpholines; Skin disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Neurokinin 1 receptor antagonists; Peptide hydrolase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting
  • Discontinued Anxiety disorders; Major depressive disorder; Schizophrenia

Most Recent Events

  • 10 Apr 2018 Merck has patent protection for aprepitant in USA, Europe and Japan
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Postoperative-nausea-and-vomiting(In adolescents, In children, Prevention) in Brazil (PO, Capsule)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Postoperative-nausea-and-vomiting(In adolescents, In children, Prevention) in Mexico (PO, Capsule)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top